DNA Topoisomerase II Mutations and Resistance to Anti-tumor Drugs

Overview

Journal Bioessays

Publisher Wiley

Specialties Biology
Cell Biology
Molecular Biology

Date 1995 Sep 1

PMID 8763829

Citations 21

Authors

Y S Vassetzky

G C Alghisi

S M Gasser

Affiliations

Soon will be listed here.

Abstract

Mutations in DNA topoisomerase II are often correlated with drug-resistance in tumor cell lines. Studies of topoisomerase II-mediated drug-resistance in various model systems, as well as the sequencing of such mutations from drug-resistant tumors, have shed light on the functional domains of topoisomerase II, on how it interacts with inhibitors, and on the different mechanisms by which cells avoid the toxic effects of many clinically important anti-tumor drugs.

Citing Articles

Molecular determinants of etoposide resistance in HL60 cells.

Alghamdi R, Ahmed F, Ibrahim S, Pushparaj P, Schulten H, Abuzenadah A Bioinformation. 2023; 18(10):894-899.

PMID: 37654838 PMC: 10465782. DOI: 10.6026/97320630018894.

Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role.

Kannampuzha S, Gopalakrishnan A Med Oncol. 2023; 40(9):264.

PMID: 37550533 DOI: 10.1007/s12032-023-02138-y.

The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.

Lotz C, Lamour V Cancer Drug Resist. 2022; 3(2):149-160.

PMID: 35582608 PMC: 9090595. DOI: 10.20517/cdr.2019.114.

Evolutionary History of TOPIIA Topoisomerases in Animals.

Moreira F, Arenas M, Videira A, Pereira F J Mol Evol. 2022; 90(2):149-165.

PMID: 35165762 DOI: 10.1007/s00239-022-10048-2.

hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.

Kania E, Carvajal-Moreno J, Hernandez V, English A, Papa J, Shkolnikov N Mol Pharmacol. 2019; 97(3):159-170.

PMID: 31836624 PMC: 6978698. DOI: 10.1124/mol.119.118315.